Objectives We aimed to cross-sectionally and longitudinally compare brain morphometry and neuropsychiatric symptoms, and evaluate their relationship, in participants with Post-Coronavirus Disease Condition (PCC) and healthy Controls. Methods At Baseline, 29 PCC (19 female; average age = 42.4 ± 12.2 years; 242 ± 156 days since infection) and 25 Controls (14 female; 44.1 ± 12.3 years) completed the NIH Toolbox Emotion, Motor and Cognition Batteries; Patient Reported Outcomes Measurement Information System (PROMIS); and structural brain MRI (thickness, areas, volumes). We compared neurobehavioral performance on the NIH Toolbox and PROMIS and structural brain morphometry for 34 cortical regions and 8 subcortical volumes, between PCC and matched Controls at Baseline (∼8 months post-infection) and 11 PCC and 7 Controls at a Follow-Up visit (∼3 years post-infection). Results At Baseline, PCC had significantly larger putamen and amygdala (FDR-corrected p = 0.04; +5.3 and 5.9 %) and a trend for larger hippocampus and accumbens (uncorrected-p = 0.012 and 0.027, +5.1 and 12.9 %) than Controls. PCC also tended to have 4 thicker cortices (p = 0.010–0.049; +3.6–6.5 %), 6 larger surface areas (p = 0.009–0.023; +5.9–8.6 %), and 9 larger cortical volumes (p = 0.003–0.008; +4.2–10.7 %). These abnormal measures were associated with more anxiety, depression, and pain ( r = 0.5–0.75; p = 0.005–0.04). At Follow-Up, PCC had more sadness, fear, pain, and fatigue compared to Controls. However, group differences in morphometry diminished and PCC neurobehavioral performance tended to improve. Conclusions Structural abnormalities in PCC suggest compensatory processes such as enhanced myelination or neurogenesis, rather than neuroinflammation, which in turn may contribute to persistent neurobehavioral symptoms. However, these alterations and symptoms may improve three years after infection.
Journal
Open Access
NeuroImmune Pharmacology and Therapeutics
-
Editor-in-Chief:
Howard E. Gendelman
Language:
English
First published:
May 20, 2022
Publication Frequency:
4 issues per year
About this journal
Objective
NeuroImmune Pharmacology and Therapeutics is the official peer-reviewed journal of the Society on NeuroImmune Pharmacology. Owned by the Society, the open-access journal showcases cutting-edge research in four core areas: neuroscience, immunology, pharmacology, and therapeutics. Published manuscripts focus on any one of these subject areas and/or their intersections to advance basic, clinical, and translational science.
Specific aims:
- To promote diverse neuroimmune research activities in molecular, biochemical, genetic, and pathogenetic studies that advance pharmacologic and therapeutic scholarship.
- To present cutting-edge laboratory, translational, and clinical research on substance use disorders (biology, pathophysiology, behavior, and structure-function relationships) and neurodegenerative, neuroinfectious, metabolic, inflammatory, behavioral, and infectious diseases.
- To present therapeutic works with molecular, structural-surgical (interventions), and biochemical approaches that serve to ameliorate, delay, or arrest disease onset and/or progression.
- To present new, highly interactive, and cross-disciplinary research that intersects the fields of drug delivery, neuroscience, and immunology relevant to modulating or transforming the neuroimmune axis.
- To provide a platform for divergent and prospective points of view, letters, and/or brief communications on recent topics of immediate interest.
- To foster immediate/relevant information exchanges for neuroimmune therapeutics, disease prevention and treatment strategies in support of topical supplementary reviews with interactions and/or support of the views and directions of the Society on Neuroimmune Pharmacology.
- To support and encourage scientific exchange between Society members, authors in or outside the field of neuroimmune therapeutics, and reaching into an international field of investigators that span the globe.
- To promote scholarly submissions on the etiology, prevention, and treatment of neuroimmune disorders (including clinical trials) where therapeutic intervention has proven viable and active.
- To define the neuroimmunomodulator properties of neuroimmune innervations and regeneration, and of endogenous and exogenous neuroimmunomodulator substances, that would include (but are not limited to) hormones, neuropeptides, neurotransmitters, cytokines, chemokines, and abused substances.
- To advance actively developing fields of research in neuroimmune pharmacology (including but not limited to nano-medicine, therapeutics, technology, and gene editing).
- To promote translational research in general and, in particular, a better understanding of the role played by neuroinfectious diseases, inflammation, and stress in disorders of the neuroimmune axis.
- The overarching scope of the journal is to provide a platform for promoting the Society’s research and to extend that vision on a global scale in basic, clinical, and translational science.
-
January 1, 2000
Submission
You can easily submit your manuscript online. Simply go to http://mc.manuscriptcentral.com/nipt and you will be guided through the whole submission and publishing process.
Additionally, the Template for Ethical and Legal Declarations needs to be customized by the submitting author on behalf of all others and uploaded as a separate doc-file at the time of the original submission. Instructions on how to make declarations can be found here.
- Open Access publication
- Research freely available for all to read and download
- Authors retain copyright – articles published under the Creative Commons Attribution (CC-BY-4.0) License
- Rapid publication times
- Free publication of color figures
- Every article easily discoverable because of Search Engine Optimization (SEO) and comprehensive abstracting and indexing services
- Professional sales and marketing activities
Submission process
- Submission of your manuscript via our submission management tool following the Information for Authors
- Single-blind peer review process
- A decision on your paper is aspired within 4-5 weeks
- Accepted articles are published online approx. 3 weeks after acceptance
- Publication language is English. Manuscripts must be written in clear and concise English
- The Template for Ethical and Legal Declarations are required for submission
- NIPT follows Tier 3 of our Data Sharing Policy.
Authors are required to provide a data availability statement. Please refer to the Data Sharing Policy for guidance on how to write a data availability statement. - If you have any general questions please visit our FAQ for authors
- For more detailed information please contact the NIPT Editorial Office nipt@unmc.edu
We are looking forward to receiving your manuscript!
Editor-in-Chief
Howard E. Gendelman, M.D.
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center
Omaha, NE, USA
Managing Editor
Amy Sather
University of Nebraska Medical Center
Omaha, NE, USA
Contact: nipt@unmc.edu
Editors
Senior Editor (North America)
Kalipada Pahan, Ph.D.
Department of Neurological Sciences
Rush University Medical Center
Chicago, IL, USA
Senior Editor (Asia and Pacific Rim)
Raymond Chuen-Chung Chang, Ph.D.
School of Biomedical Sciences
The University of Hong Kong
Hong Kong, China
Section Editor (Neuroactive and Abused Substances)
Sabita Roy, Ph.D.
Departments of Surgery, Microbiology and Immunology, and Biochemistry
University of Miami Miller School of Medicine
Miami, FL, USA
Section Editor (Imaging and Biomarkers)
Linda Chang, M.D., M.S.
Departments of Diagnostic Radiology and Nuclear Medicine, and Neurology
University of Maryland School of Medicine
Department of Neurology, Johns Hopkins School of Medicine
Baltimore, MD, USA
Section Editor (Neurotherapeutics)
Harris A. Gelbard, M.D., Ph.D.
Department of Neurology
University of Rochester Medical Center
Rochester, NY, USA
Section Editor (Neurodegenerative Disorders)
Tsuneya Ikezu, M.D., Ph.D.
Department of Neuroscience
Mayo Clinic Florida
Jacksonville, FL, USA
Section Editor (Neuroimmunology)
Steven Jacobson, Ph.D.
Viral Immunology Section
National Institute of Neurological Disorders and Stroke
Bethesda, MD, USA
Section Editor (Nanomedicine)
Ram I. Mahato, Ph.D.
Department of Pharmaceutical Sciences
University of Nebraska Medical Center
Omaha, NE, USA
Section Editor (Cell Signaling and Immunity)
Thomas J. Rogers, Ph.D.
Center for Inflammation and Lung Research
Lewis Katz School of Medicine of Temple University
Philadelphia, PA, USA
Section Editor (Immunopharmacology)
Eliseo Eugenin, M.D., Ph.D.
Department of Neuroscience
University of Texas Medical Branch
Austin, TX, USA
Section Editor (Inflammatory Transformation)
Stanley H. Appel, M.D.
Houston Methodist Neurological Institute
Houston Methodist
Houston, TX, USA
Section Editor (Material Science and Drug Delivery)
Dan Peer, Ph.D.
Laboratory of Precision NanoMedicine
Tel Aviv University
Tel Aviv, Israel
Section Editor (Infectious Disease)
Vicente Soriano, M.D., Ph.D.
Health Sciences School and Medical Center
International University of La Rioja
Madrid, Spain
Section Editor (Neurochemistry, Neuroimmunity, and Neuroanatomy of Dementia)
Rosemarie M. Booze, Ph.D.
Department of Psychology
University of South Carolina
Columbia, SC, USA
Editorial Board
Chandravanu Dash, Ph.D.
Vanderbilt Institute for Infection, Immunology and Inflammation
Vanderbilt University Medical Center
Nashville, TN USA
Siddappa Byrareddy, Ph.D.
Department of Pharmacology & Experimental Neuroscience
University of Nebraska Medical Center
Omaha, NE USA
Pooja Jain, Ph.D.
Microbiology & Immunology
Drexel University College of Medicine
Philadelphia, PA USA
Olimpia Meucci, M.D., Ph.D.
Pharmacology & Physiology
Drexel School of Medicine
Philadelphia, PA USA
Dionna Williams, Ph.D.
Molecular and Comparative Pathobiology
Johns Hopkins Medicine
Baltimore, MD USA
Yuri Persidsky, M.D., Ph.D.
Department of Pathology and Laboratory Medicine
Lewis Katz School of Medicine
Philadelphia, PA USA
Larisa Poluektova, M.D., Ph.D.
Department of Pharmacology & Experimental Neuroscience
University of Nebraska Medicine
Omaha, NE USA
Ronald Ellis, M.D., Ph.D.
Neuroscience and Psychiatry
University of California, San Diego
San Diego, CA USA
Johnny He, Ph.D.
Department of Immunology and Infection
Rosalind Franklin University of Medicine and Science
North Chicago, IL USA
Nazira El-Hage, Ph.D.
Department of Immunology & Nano-Medicine
Florida International University
Miami, FL USA
Shilpa Buch, Ph.D.
Department of Pharmacology & Experimental Neuroscience
University of Nebraska Medical Center
Omaha, NE USA
Wenzhe Ho, M.D., MPH
Department of Pathology and Laboratory Medicine
Lewi Katz School of Medicine
Philadelphia, PA USA
Natalie May Zahr, Ph.D.
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, CA USA
Advisory Board
Sulie L. Chang, Ph.D. *
Institute of NeuroImmune Pharmacology and Department of Biological Sciences
Seton Hall University
South Orange, NJ, USA
Santosh Kumar, Ph.D. *
Department of Pharmaceutical Sciences
College of Pharmacy
University of Tennessee Health Science Center Memphis
Memphis, TN, USA
Jean M. Bidlack, Ph.D. *
Department of Pharmacology and Physiology
University of Rochester Medical Center
Rochester, NY, USA
Sanjay B. Maggirwar, Ph.D., M.B.A. *
Department of Microbiology, Immunology, and Tropical Medicine
The George Washington University
Washington, D.C., USA
Carol J. Swarts, M.D. **
University of Nebraska Medical Center
Seattle, WA, USA
Robert M. Eisenberg, J.D., M.A. **
Omaha, NE, USA
* Members of the Journal Publishing Committee of the Society on NeuroImmune Pharmacology.
** Major philanthropic supporters of the journal, NeuroImmune Pharmacology and Therapeutics.
NeuroImmune Pharmacology and Therapeutics is covered by the following services:
- Baidu Scholar
- CNKI Scholar (China National Knowledge Infrastructure)
- CNPIEC - cnpLINKer
- Dimensions
- EBSCO Discovery Service
- Google Scholar
- J-Gate
- Naver Academic
- Naviga (Softweco)
- Primo Central (ExLibris)
- ReadCube
- ScienceON (Korea Institute of Science and Technology Information)
- Scilit
- Semantic Scholar
- Summon (ProQuest)
- TDNet
- WorldCat (OCLC)
- X-MOL
- Yewno Discover
Topics
Journal information
Additional information
eISSN:
2750-6665
Language:
English
Publisher:
De Gruyter
Additional information
First published:
May 20, 2022
Publication Frequency:
4 issues per year
